Speaker illustration

Doctor Alexander Kharlamov

De Haar Research Task Force, Rotterdam (Netherlands (The))

Member of:

European Society of Cardiology
EAPCI
Heart Failure Association

Dr Kharlamov has 26 years of the clinical experience in general cardiology (since 1996; a Consultant Physician since 2007; a Board-Certified Cardiologist since 2010), 21 years of the translational research in nanomedicine and biomedical engineering (since 2001), and about 15 years of the bench-to-bedside studies in interventional cardiology and advanced cardiovascular imaging (a leader of the research group since 2007) including artificial intelligence/ digital medicine, vascular biology and pathology, RTD of medical devices (bioresorbable scaffolds and stents). Since 2007-2009 he has been working in some institutes in the Netherlands (UMC St Radboud, Nijmegen; UMCG, Groningen; Erasmus MC, Rotterdam). His ORCiD profile is orcid.org/0000-0003-4631-1261, ResearcherID: I-3692-2015, SCOPUS author ID: 56721449700, NCBI/ PubMed profile: akharlamov@orcid.

Can we reverse atherogenesis with the eradication of toxic LDL-C? A comparative pooled analysis of selected therapies in quest of the revolutionary approach

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Revascularisation

Session: Coronary Artery Disease (Chronic) ePosters

Thumbnail

Haplogroup disparities of atheroregression in white and east asian populations in lipid-lowering and invasive studies

Event: ESC Congress 2018

Topic: Revascularisation

Session: Coronary artery disease - Diagnosis, pharmacotherapy and revascularisation

Thumbnail

This platform is supported by

logo Novo Nordisk